Bibliography
- MARTINDALE W: The Extra Pharmacopeia. (Edition 30). Reynolds JEF (Ed.) The Pharmaceutical Press (1993).
- COOKSON W: The alliance of genes and environment in asthma and allergy. Nature (1999) 402 (Suppl.):B5–B11.
- ••This article, together with others in this supplement providea comprehensive review of asthma and allergy.
- FROST AND SULLIVAN MARKET REPORT: US allergy and asthma therapeutic markets. (1997):5492–52.
- FROST AND SULLIVAN MARKET REPORT: European asthma and allergy treatment markets. (1996):3262–52
- MANNING AM, LEWIS AJ: Transcription factors, rheumatoid arthritis and the search for improved antirheumatic agents. Rheumatoid Arthritis ID Research Alert (1997) 1 (2):65–73.
- HEATH PK:Use of anti-TNF-alpha therapies as potential treatments for rheumatoid arthritis. Rheumatoid Arthritis ID Research Alert (1997) 1(5) :235–239.
- FROST AND SULLIVAN MARKET REPORT: US arthritis therapeutic product markets. (1996):5483–52.
- SCRIP REPORT: Multiple sclerosis and amyotrophic lateral sclerosis. PJB Publications Ltd., London, UK (1997).
- FROST AND SULLIVAN MARKET REPORT: European organ transplant therapy and diagnostic markets. (1999): 3748–52.
- SPRINGER TA: Traffic signals for lymphocyte recircula-tion and leukocyte emigration: the multi-step paradigm. Cell (1994) 76:301–314.
- •Excellent review article which captures much of the original thinking about the role of adhesion molecules in cell migration.
- MULLER-LADNER U, ELICES MJ, KREIGSMANN JB, et al.: Alternatively spliced CS-1 fibronectin isoform and its receptor VLA4 in rheumatoid arthritis. J. Rheumatol. (1997) 24:1873–1880.
- PRETOLANI M, RUFFIE C, LAPA E SILVA JR, et al: Antibody to very late activation antigen 4 prevents antigen induced bronchial hyperreactivity and cellular infiltration in guinea pig airway. J. Exp. Med. (1994) 180(3) :795–805.
- •One of the earliest demonstrations indicating VLA4 as a potential target in allergic hypersensitivity.
- METZGER WJ, RIDGER V, TOLLEFSON V, et al: An ti-VIA4 antibody and CS-1 peptide inhibitor modifies airway inflammation and bronchial airway hyperresponsive-ness in the allergic rabbit. J. Allergy Clin. Immunol (1994) 93:183.
- •One of the earliest demonstrations indicating VLA4 as a potential target in allergic hypersensitivity.
- CHUNG KF, BARNES PJ: Cytokines in asthma. Thorax (1999) 54(9):825–857.
- CORRY DB, FOLKESSON HG, WARNOCK ML, et al.: Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreac-tivity. J. Exp. Med. (1996) 1 83 (1) :109–117.
- •Study dissects the roles of IL-4 and IL-5 in a model of allergic pulmonary inflammation.
- VASSALLI P: The pathophysiology of tumour necrosis factors. Ann. Rev. Immunol. (1992) 10:411–452.
- TRINCHIERI G: Interleukin 12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen specific immunity. Ann. Rev. Immunol. (1995) 13:251–276.
- LEONARD JP, WALDBURGER KE, GOLDMAN SJ: Preven-tion of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.1 Exp. Med. (1995) 181:381–386.
- •An early demonstration of the underlying role for IL-12 in disease induction.
- BAGGIOLINE M, DEWALD B, MOSER B: Human chemokines: an update. Ann. Rev. Immunol. (1997) 15:675–706.
- PLATER-ZYBERK C, HOOGEWERF AJ, PROUDFOOT AE,POWER CA, WELLS TN: Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol. Lett. (1997) 57 (1-3) :117–120.
- LODDICK SA, MACKENZIE A, ROTHWELL NJ: An ICE inhibitor, z-VAD-DCB, attenuates ischaemic brain damage in the rat. Neuroreport (1996) 7(9):1465–1468.
- MOHLER KM, SLEATH PR, FITZNER JN, et al.: Protectionagainst a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (1994) 370:218–220.
- CARTY TJ, MARFAT A: COX-2 inhibitors: potential for reducing NSAID side-effects in treating inflammatory diseases. Emerging Drugs (1996) 1:391–411.
- SOUNESS JE, FOSTER M: Potential of phosphodiesterase Type 4 inhibitors in the treatment of rheumatoid arthritis. Curr. Res. Rheumatoid Arthritis (1998) 2 (6):255–268.
- •Good review on the problems faced by early stage PDE4 inhibitors and the strategies taken by pharmaceutical companies to overcome them.
- HANKS SK, HUNTER T: Protein kinases 6. The eukary- o tic protein kinase sup er family: kinase (catalytic) domain structure and classification. FASEB J. (1995) 9:576–596.
- •Good review on kinase classification.
- ADAMS JL, LEE DL: Recent progress towards the identi-fication of selective inhibitors of serine/threonine protein kinases. Curr. Opin. Drug Disc. Dev. (1999) 2(2):96–109.
- RIESE RJ, CHAPMAN HA: Cathepsins and compartmen-talisation in antigen presentation. CUIT. Opin. Immunol. (2000) 1 2 (1):107–113.
- BAEUERLE PA, HENKEL T: Function and activation ofNFkappaB in the immune system. Ann. Rev. Immunol. (1994) 12:141–180.
- •Excellent review which details the role of NF-kappaB in immune activation.
- DIDONATO JA, HAYAKAWA M, ROTHWARF DM, ZANDIE, KARIN M: A cytokine responsive IkB kinase that activates the transcription factor NFkB. Nature 388:548–554.
- OUYANG W, LOHNING M, GAO Z: Stat-6 independentGATA-3 autoactivation directs IL-4 independent Th2 development and commitment. Immunity (2000) 12 (1) :27–37.
- DYER MR, COHEN D, HERRLING PL: Functionalgenomics: from genes to new therapies. Drug Disc. Today (1999) 4(3):109–114.
- BIOGEN: Company communication (30 March 2000).
- ISIS PHARMACEUTICALS: Company press release (18 January 2000).
- SAKAN T, SUZUKI N, HIROSE Y, et al: Mechanisms of KE-298 2-acetylthiomethy1-3-(4-methylbenzoyl) proprionic acid to suppress abnormal synovial cell functions in patients with rheumatoid arthritis. J Rheumatol. (1997) 24 (1 1) :2213–2220.
- IIJIMA H, TAMURA G, HSIUE TR, et al: Suplatast tosilate inhibits late response and airway inflammation in sensitised guinea pigs. Am. J. Respir. Grit. Care Med. (1999) 160(0:331–335.
- NG HP, MAY K, BAUMAN JG, et al: Discovery of novel non-peptide CCR1 receptor antagonists. J Med. Chem. (1999) 42(22)4680–4694.
- BLACK R, RAUCH CT, KOZLOSKY CJ, et al: A metallopro-tease disintegrin that releases tumour necrosis factor-alpha from cells. Nature (1997) 385:729–732.
- •First reports of the successful cloning and expression of TNF-alpha converting enzyme.
- MOSS ML, JIN S-LC, MILLA ME, et al: Cloning of a disintegrin metalloproteinase that processes tumour necrosis factor-alpha. Nature (1997) 385:733–736.
- •First reports of the successful cloning and expression of TNF-alpha converting enzyme.
- GIERSE JK, MCDONALD JJ, HAUSER SD, et al: A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J. Biol. Chem. (1996) 271 (26):15810–15814.
- LEE JC, YOUNG PR: Role of CSB/p38/RK stress response kinase in LPS and cytokine signalling mechanisms. J Leukoc. Biol. (1996) 5 9 (2) :152–157.
- BADGER AM, BRADBEER JN, VOTTA B, et al: Pharma-cological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol Exp. Ther. (1996) 2 7 9 (3):1453–1461.
- HARRIS W, WILKINSON SE, NIXON JS: Recent develop-ments in protein kinase C inhibitors. Exp. Opin. Ther. Patents (1997) 7:63–68.
- BOLEN JB, BRUGGE JS: Lymphocyte protein tyrosine kinases: potential targets for drug discovery. Ann. Rev. Immunol. (1997) 15:371–404.
- •Good review on the potential for drug discovery within this class of molecules.
- AVENTIS: Press release (November 1999).
- FOX RI, HERRMANN ML, FRANGOU CG, et al.: Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. (1999) 93(3):198–208.
- CHANG DM: Irnmunoregulatory effects of a synthetic monosaccharide. Immunopharmacol. Immunotoxicol. (1995) 17:437–450.
- BOSTON LIFE SCIENCES INC.: Company press release (November 1998).
- YANAGAWA Y, HOSHINO Y, KATAOKA H, et al: FTY-720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T cell infiltration into grafts. Transplant. Proc. (1999) 31(1-2):1227–1229.
- BRAMLEY AM, LANGLANDS JM, JONES AK, et al.: Effects of IZP-94005 (contignasterol) on antigen-induced bronchial responsiveness in ovalbumin sensitised guinea pigs. Br. J Pharmacol (1995) 115 (8) : 1433–1438.
Websites
- http://iddb.com IDdb meeting report, Current Drugs Ltd. Trauma, shock, inflammation and sepsis: pathophysiology, immune consequences and therapy - 5th World Congress. (2000).
- http://iddb.com IDdb meeting report, Current Drugs Ltd. PORTER J: Medicinal chemistry in Eastern England - 1 th symposium. (2000).